Omnicell (NASDAQ: OMCL) and Allscripts Healthcare Solutions (NASDAQ:MDRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.
This is a summary of current ratings for Omnicell and Allscripts Healthcare Solutions, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Allscripts Healthcare Solutions||1||7||9||0||2.47|
Earnings and Valuation
This table compares Omnicell and Allscripts Healthcare Solutions’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Omnicell||$680.15 million||2.73||$42.68 million||($0.22)||-225.23|
|Allscripts Healthcare Solutions||$1.66 billion||1.40||$160.09 million||($1.06)||-12.12|
Allscripts Healthcare Solutions has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Allscripts Healthcare Solutions, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
96.4% of Omnicell shares are held by institutional investors. 3.8% of Omnicell shares are held by company insiders. Comparatively, 0.8% of Allscripts Healthcare Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Omnicell has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Allscripts Healthcare Solutions has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
This table compares Omnicell and Allscripts Healthcare Solutions’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Allscripts Healthcare Solutions||-11.54%||5.97%||1.96%|
Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.
What are top analysts saying about Omnicell Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omnicell Inc. and related companies.